Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Sanofi, IGM strike deal for agonist antibodies

by Michael McCoy
April 7, 2022 | A version of this story appeared in Volume 100, Issue 12

 

Sanofi will pay IGM Biosciences $150 million and potentially billions more in milestone payments as part of a deal to develop agonist antibodies for cancer and inflammatory diseases. The well-known Y-shaped IgG antibody has only two binding units. IGM says it has successfully developed IgM antibodies, which have 10 binding units. IgG antibodies are typically designed to inhibit their targets, but IGM says its deal with Sanofi focuses on agonist antibodies that stimulate cell surface receptors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.